Form 4: Director Thomas Prescott Acquires Procept Biorobotics Stock

Director Thomas M. Prescott of Procept Biorobotics Corp. has acquired restricted stock units and a stock option, increasing his beneficial ownership.

Summary

• Thomas M. Prescott, a Director at Procept BioRobotics Corp. (PRCT), reported a transaction on June 9, 2026.
• He acquired 3,315 shares of Common Stock, valued at $0, bringing his total beneficial ownership to 7,211 shares.
• Additionally, Prescott was granted a stock option to acquire 5,853 shares of Common Stock at an exercise price of $28.78, with an expiration date of June 8, 2036.
• Both the restricted stock units (RSUs) and the stock option vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, indicating continued engagement and potential alignment with future stock performance, but does not reflect new capital investment or significant operational news.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The grant of stock options provides potential future upside for the director tied to the company's stock performance.
• The vesting schedule encourages continued service and alignment with shareholder interests.

Negatives

• The reported acquisition of common stock was at a price of $0, indicating it was likely a grant or award rather than an open market purchase.
• The stock option has a strike price of $28.78, meaning the company's stock price needs to exceed this level for the option to be profitable.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning departure from the company before vesting would result in forfeiture.
• The value of the stock option is dependent on the future stock price performance of Procept BioRobotics Corp.

Future Outlook

The future outlook for the acquired securities is tied to the company's stock performance, with vesting contingent on continued service and the stock price needing to exceed $28.78 for the stock option to be in-the-money.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as potential indicators of management's confidence in the company's future performance. The acquisition of equity awards is a common compensation practice in the biotechnology sector.

Stakeholder Impact

• Shareholders: The transaction may be interpreted as a positive signal of director confidence, potentially influencing investor sentiment. The vesting schedule aligns director incentives with long-term shareholder value.
• Employees: The compensation structure for directors, including equity awards, is part of the broader corporate governance framework that can indirectly affect employee morale and retention.
• Management: Reinforces the alignment of director compensation with company performance.

Next Steps

• Continued service by Thomas M. Prescott through the vesting dates for the RSUs and stock option.
• Monitoring of Procept BioRobotics Corp.'s stock price relative to the $28.78 option exercise price.

Key Dates

Keywords

Form 4, SEC Filing, Procept BioRobotics Corp, PRCT, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading, Equity